leisure time -WSS

leisure time

author：knowledge 2025-10-02 10:48:11 - browse：4

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： J&J lung cancer data amount to new salvo against AstraZeneca

WSS

Why CTE doesn’t keep Americans from enjoying the Super Bowl

FDA clears Verve to begin U.S. study of gene

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

ADCs take center stage as promising cancer treatments

UnitedHealth, Optum discontinue NaviHealth name

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Wikipedia

leisure time

focus

Supreme Court strikes down use of affirmative action

Padmanee Sharma of MD Anderson at center of lawsuit over credit

In age of alternative facts, a scholarly course on calling out crap

Smaller biotechs seek to piggyback on weight loss drug boom

Medical records are filled with copy

UnitedHealth, Optum discontinue NaviHealth name

Heart attack and stroke risk calculators need revising

The CDC's new social media misinformation war

George Santos makes 1st court appearance after pleading not guilty to 13 counts

STAT Summit: Meghan O’Rourke on making chronic illness visible

hotspot

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Global cancer cases to surge 77% by 2050, WHO report says

Gene therapy for Afghan refugees’ infant will be fully covered

Global cancer cases to surge 77% by 2050, WHO report says

The problems with dementia villages

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Wikipedia

leisure time

entertainment

Wikipedia